The double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease (AD) has been widely used in experimental studies. β-Amyloid (Aβ) peptide is excessively produced in AD mouse brain, which affects synaptic function and the development of central nervous system. However, little has been reported on characterization of this model. The present study aimed to characterize this mouse AD model and its wild-type counterparts by biochemical and functional approaches. Methods Blood samples were collected from the transgenic and the wild-type mice, and radial arm water maze behavioral test was conducted at the ages of 6 and 12 months. The mice were sacrificed at 12-month age.
in the brain [1, 2] . Aβ peptides are derived from β-amyloid precursor protein (APP) through sequential proteolytic cleavage by β-and γ-secretases, while sequential cleavage of APP by α-and γ-secretases does not produce Aβ peptides [1, 2] . Aβ peptides form oligomers and aggregates/ deposits in the brain, which affect synaptic function and result in neuronal cell death and neuroinflammation [1, 2] .
Early onset or familial AD results from mutations in genes encoding APP, γ-secretase component presenilin 1 (PS1) or PS2 [1] [2] [3] [4] . APP gene is located on human chromosome 21.
Down's syndrome individuals with 3 copies of chromosome 21 (trisomy 21) and 3 copies of APP gene produce a large amount of Aβ peptides in the brain, resulting in mental retardation or cognitive impairment. These patients exhibit impairment of physical development and functions, an increased risk of developing epilepsy, and early onset of dementia. Transgenic animal models carrying mutant human APP or/and PS1 gene(s) have been generated and widely used in experimental studies as well as in drug development and testing. The transgenic mice co-expressing mutated PS1 and APP [3, 4] develop Alzheimer's amyloid pathology much earlier than do the mice expressing only APP. In contrast, co-expression of wild-type human PS1
gene with the mutant human APP gene does not have any impact on the rate of amyloid formation [3, 4] . 
Blood collection Blood samples (approximately 250
μL for each mouse) were obtained via cheek vein at the ages of 6 and 12 months and stored in EDTA collection tubes. Blood samples were centrifuged at 1 500 g for 10 min at room temperature, and plasma was collected for Aβ and 8-hydroxydeoxyguanosine (8-OHdG) ELISA assays.
Blood pellet containing white blood cells was used for DNA extraction.
Genotyping
The mice were genotyped within 4 months after they were received. Genomic DNA was extracted from blood pellet containing white blood cells according to the previous descriptions [5] . All mice were geno- [6, 7] . Briefly, the platform (8 cm in diameter) was submerged (approximately 1 cm under water) at the end of one of the 6 swim arms in the water tank. Visual cues were placed as shown in 
Immunohistochemistry
The left hemisphere of the mouse brain was fixed in 4% paraformaldehyde overnight, and then immersed in 20% sucrose for 24 h. After that, the brain tissue was embedded in optimal cutting temperature compound. The tissue was frozen-cut into 10-μm thick coronal sections. Immunohistochemical staining was performed using a LSAB+ System-HPR kit (Dako, Denmark) following the manufacturer's protocols as described previously [8] . Anti-Aβ primary antibody (6E10, Covance
Research Products; Emeryville, CA, USA) was diluted at 1:
1 000. The HRP-conjugated secondary antibody in the kit was used following manufacturer's instructions.
Secretase activity assays In vitro activity assays for
α-, β-and γ-secretases in brain homogenate were performed according to previous descriptions with modifications [9] . Triton X-100 as described previously [10] . The reaction expressed as fluorescent units per μg protein [9] .
Statistical analysis Each of the in vitro experiments
or assays was performed in duplicate or triplicate. The experiments or assays were repeated for at least 3 times.
Results were expressed as mean ± SD. [6, 7] . P < 0.05 was considered as statistically significant.
Results

Premature death and Aβ levels in brain
Before the age of 6 months, the premature death rate of the transgenic mice was about 35%. Seizures were observed in the transgenic mice, which might be one of the factors leading to premature death. All the dead mice were dissected and no gross pathological abnormality was observed. After 6 months of age, the survival of the transgenic mice was stable and death rarely occurred. In contrast, none of the wildtype mice died during the whole period of experiment.
However, the body weight of the transgenic and wild-type mice was similar during the whole period of experiment.
ELISA analysis of Aβ levels in the brain tissues from the dead transgenic mice showed that the level of total Aβ was about 50-100 pg/mg protein in the whole brain homogenate, while the level of total Aβ 1-42 ranged from 500-1 100 pg/mg protein. [11, 12] and may be also one of the factors responsible for premature death. 
The levels of Aβ
Behavioral performance
As shown in Fig. 3 , the transgenic mice at the age of 6 months made significantly more errors (Fig. 3A) and showed significantly longer latencies (Fig. 3B ) in overall trial 4 and trial 5, compared with the age-matched wild-type mice (One-way ANOVA, *** P < 0.001). Similar results were found at the age of 12 months for transgenic and wild-type mice (Fig. 4) . In addition, for transgenic mice, the errors made at 12-month age in overall trial 4 were significantly more than the errors made at 6-month age [(3.39 ± 0.55) vs (2.36 ± 0.36), t-test, *** P < 0.000 1)] (Fig. 5) . On the contrary, the 12-monthold wild-type mice made less errors compared to the wildtype mice at 6-month age, but with no statistical difference [(0.75 ± 0.37) vs (0.96 ± 0.19), t-test, P = 0.125 8] (Fig. 5 ).
3.5
The level of α-, β-and γ-secretase activity in brain tissues As shown in Fig. 6 , α-secretase activity in the frontal cortex, posterior cortex and hippocampus of transgenic mice was significantly higher than that of wildtype mice (Fig. 6 ) (t-test, P < 0.05). This may result from compensative response due to over-production of APP or
Aβ peptides in these brain regions of transgenic mice. The level of β-secretase activity was significantly higher in the brainstem/midbrain of the transgenic mice than in the corresponding regions of wild-type mice (Fig. 6 ) (t-test, P < 0.05), while the level of γ-secretase activity in the cerebellum of wild-type mice was significantly higher than that of transgenic mice ( As shown in Fig. 7 , the levels of total Aβ 1-40 and Aβ peptides in different brain regions of transgenic mice varied greatly. Aβ 1-40 level in frontal cortex was significantly higher than those in other brain regions ( (Fig. 7B) .
Comparison of Aβ 1-40 with Aβ 1-42 levels in different (Fig. 8) . Besides, the level of Aβ 1-42 was 235%, 122%, and 150% of Aβ 1-40 level in brainstem/midbrain, striatum and the remaining brain tissues (Fig. 8) ,
respectively, but there was no statistical difference due to variations. Immunohistochemistry (IHC) detected deposits of Aβ peptides (plaques) in the brain of transgenic mice but not in the brain of wild-type mice (Fig. 9) . The density of Aβ plaques found in transgenic mouse brain by IHC correlated well with the ELISA results for Aβ peptides.
Discussion
In the present study, all of the mice used were female because we observed in our other studies that male trans- peptides predispose to aggregate and form oligomers and plaques while Aβ 1-40 is more soluble [11, 12] . Thus, Aβ 1-42 peptides are much more toxic to neuronal cells than Aβ 1-40 and can trigger stronger inflammatory responses in cells [11] [12] [13] [14] [15] .
In addition, seizures were observed in transgenic mice but not in wild-type mice, which may be another cause leading to premature death of the transgenic mice.
The levels of Aβ peptides in the blood of transgenic mice were similar at the ages of 6 and 12 months, suggesting that the levels of Aβ peptides in blood reached a plateau at the age of 6 months. Aβ peptides, especially Aβ 1-40 peptides, can be transported bi-directionally across the blood-brain barrier [8, 16, 17] . Here we found that in 6-and 12-month old transgenic mice, Aβ 1-40 level was significantly higher than Aβ 1-42 level in the blood (Fig. 2) . This further indicates that Aβ 1-40 is more soluble than Aβ and is easier to be transported and cleared from the brain across the blood-brain barrier into blood circulation. As onset AD in human [1] [2] [3] [4] . Despite the fact that the transgenic mice carry a mutant human PS1 transgene (PS1 with deletion of exon 9), our assays showed that the activity of γ-secretase in different brain regions was essentially similar to that of wild-type mice. One potential explanation is that the γ-secretase containing human mutant PS1 does not lead to higher γ-secretase activity but is more efficient in cleaving APP into Aβ 1-42 peptides. Alternatively, γ-secretase containing human mutant PS1 may also be less efficient in cleaving the commercial γ-secretase assay substrate used in this assay than in cleaving APP. This PS1 mutation is known to be more efficient in generating Aβ 1-42 peptides which predispose to aggregate and form Aβ plaques in the brain. In contrast, α-secretase activity in 3 brain regions of transgenic mice was significantly higher than that in the same brain regions of wild-type mice. Since a large amount of APP protein is produced in the brain of transgenic mouse, α-secretase may be consequently induced to process the excessive amount of APP protein.
Behavioral tests showed that the transgenic mice had significant memory deficits at the age of 6 months as compared to the age-matched wild-type mice. The deficit was worse at the age of 12 months in terms of errors made in overall trial 4, compared to their performance at the age of 
